Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

VUV Analytics welcomes industry veteran Lou Cheng to the team Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb VUV Analytics introduces HYDRA™: A breakthrough Vacuum Ultraviolet Detector for Liquid Chromatography Novadip appoints Soumya Chandramouli as Chief Financial Officer San José City Council unanimously approves next phase of San José Airport Connector Project NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology
Back To News
Ventyx Biosciences
June 6, 2020

Ventyx Biosciences

Developing selective inhibitors of TYK2 for autoimmune diseases.

Cookie Policy Website powered by 100% renewable energy Privacy Policy